Secukinumab
Secukinumab is a human immunoglobulin G1/κ monoclonal antibody targeting interleukin-17A. In clinical trials, 77-81% of the secukinumab patients achieved a PASI75 response in 12 weeks. As well as in chronic plaque psoriasis, secukinumab has also been found effective and safe as monotherapy in nail a...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
Galenos Publishing House,
2022-04-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|